Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Topic

You searched for:

ASSOCIATION OF CANCER CARE CENTERS Executive Summary: ACCC Working Summit on Biomarker Testing Solutions for EHR Integration Advances in precision medicine are leading to more patients receiving biomarker-driven therapies, but complex testing workflows still make it difficult for oncologists to efficiently order cancer biomarker tests. To address these challenges, the Association …
Thoracic Malignancies Non-Small Cell Lung Cancer Small Cell Lung Cancer Mesothelioma Thoracic Malignancies Best of ASCO 2024 Muhammad Furqan, MBBS Professor, Dept. Internal Medicine University of Iowa Health Care August 24, 2024 Disclosures: Thoracic Malignancies Best of ASCO 2024 Institutional research funding: AbbVie, Amgen, Aprea, Astellas, AstraZeneca, …
PowerPoint Presentation Proto-oncogene HRAS transcript level predicts overall survival in locally advanced colorectal cancer Donghyun Kim, MD PhD Hematology and medical oncology fellow University of Iowa“I have no conflict of interest to declare” HRAS as a prognostic biomarker in locally advanced colorectal cancer Hanahan D, Weinberg RA. Hallmarks of cancer: the …
PowerPoint Presentation NAOMI FEI MD, MS 8/24/24 Upper GI Malignancies 2Carver College of Medicine Disclosure • I have no relevant financial relationships with ineligible companies to disclose. 3Carver College of Medicine Outline • Esophageal/Gastric Cancer • ESOPEC • ARMANI • Pancreatic Cancer • RTOG 0848 • GIANT • Cholangiocarcinoma • …
PowerPoint Presentation Metastatic Colon Cancer Dulabh K. Monga MD Associate Professor of Medicine Drexel University School of Medicine Allegheny Health Network Cancer Institute Pittsburgh Disclosures Speakers Bureau: Bristol Myers Squibb Astra Zeneca Advisory Board: Astra Zeneca Key Studies in Metastatic Colorectal Cancer ASCO 2024 ➢ Checkmate …
GI Oncology Update: Adjuvant & Metastatic Colorectal Cancer Insert->Header and Footer->Type Customizable Name Best of ASCO 2024 Updates in Neoadjuvant and Adjuvant Treatment of Colon & Rectal Cancers, Anal Cancers Saima Sharif, MD MS August 24, 2024 Disclosure • I have permission to use slides from Annual Meeting 2024 • Saima Sharif, MD MS reports: • Grant/research …
Example of the Presentation Title Slide Leukemias Notable abstracts in leukemia and MDS Grerk Sutamtewagul, MD Clinical Associate Professor, University of Iowa August 24, 2024 Best of ASCO 2024 - Iowa City 2Carver College of Medicine Disclosure • I received research fundings from Arog Pharmaceuticals, Syros, Novartis, Gilead, Bristol Myers, Kura Oncology, …
Adjuvant Osimertinib for Resected Stage IB-IIIA Non-Small Cell Lung Cancer Trends in Hematopoietic Cell Transplantation in Acute Myeloid Leukemia from 2004-2020 Aditya Ravindra MD Hematology & Medical Oncology Fellow Mentor: Prajwal Dhakal MD Iowa Oncology Society 2024 Best of ASCO Financial Disclosures This work was supported by clinical research funds from the Holden …
PowerPoint Presentation Vincent Wagner, MD Gynecologic Oncology Best of ASCO I have no relevant financial relationships or conflicts of interests to disclose Disclosure G Y N E C O L O G I C O N C O L O G Y – B E S T O F A S C O CERVIX CANCER G Y N E C O L O G I C O N C O L O G Y – B E S T O F A S C O RTOG 0724/GOG-0724 G Y N E …
PowerPoint Presentation August, 24, 2024 SARCOMA Disclosures • Sponsored Research- Cogent Biosciences, Inc. • Sponsored Research- Ascentage Pharma Group, Inc. • Advisory Board: Deciphera Pharmaceuticals • “A riddle wrapped in a mystery inside an enigma” • Very challenging to study and understand • Derived from mesenchymal stem cells (behave differently …
PHASE Ib PILOT STUDY OF ITACITINIB WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA Kadia T, Jain A, Ravandi F, Borthakur G, Jabbour E, Montalban-Bravo G, Adewale L, Pierce S, Lacke C, Brandt M, Short N, Jain N, Burger J, Ferrajoli A, Wierda W, Kantarjian H Presenter:- Akhil Jain, MD Fellow, Holden Comprehensive Cancer Center Disclosure- none Background …
Updates on Neoadjuvant Immune therapy in Melanoma Neoadjuvant Immune Therapy in Melanoma Updates from ASCO 2024 Asad Javed, MBBS Holden Comprehensive Cancer Center University of Iowa Disclosures • Immunocore: Member, steering committee Why consider a Neoadjuvant Approach? • Resection of tumor bulk removes the immunologic targets as well as the …
PowerPoint Presentation August 24, 2024 Multiple Myeloma ASCO 2024 Highlights T I T L E Disclosures • No financial disclosures. Holden Comprehensive Cancer Center Acknowledgements • Thank you to the abstract presenters for use of their slides: –Dr. Facon (Abstract # 7500) –Dr. Trudel (Abstract # LBA105) –Dr. Touzeau (Abstract # 7507) –Dr. Leleu …
Maximizing the Therapeutic Potential of PRRT for Neuroendocrine Tumors Maximizing the Therapeutic Potential of PRRT for Neuroendocrine Tumors Udhayvir Singh Grewal, MD University of Iowa Hospitals and Clinics, Iowa City, IA WHO Classification of NENs Therapeutic paradigm for NETs Chauhan et al. 2022 CABINET ESMO 2023 Peptide Receptor …
Example of the Presentation Title Slide Best of ASCO 2024 Lymphoma Abstracts PRESENTED BY: NANMENG YU, MD, PHD, UNIVERSITY OF IOWA August 24, 2024 2Carver College of Medicine Disclosure • I have no relevant financial relationships with ineligible companies to disclose. 3Carver College of Medicine Classical Hodgkin Lymphoma (cHL) • Bimodal presentation • …
Virtual Program Schedule Making Small Cell Lung Cancer Not So Small Anymore: A REVIEW OF EPIDEMIOLOGY, TREATMENT LANDSCAPE, AND LONG-TERM MANAGEMENT Tuesday, September 17, 2024 Wednesday, September 18, 2024 Thursday, September 19, 2024 Mark Socinski, MD Attending Physician Executive Medical Director AdventHealth Cancer Institute Orlando, Florida Frank Weinberg, MD, PhD Assistant …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. TACOS ONCOLOGY DRUG NEWSLETTER A U G U S T 2 0 2 4 FDA APPROVALS Tepylute (SH-105) The FDA has approved Tepylute (SH-105), a ready- to-dilute formulation of an existing treatment for breast and ovarian adenocarcinoma.1 The original …
SOCIAL DRIVERS OF HEALTH PROVIDER SURVEY RESULTS: A FOCUS ON METASTATIC BREAST CANCER 1 BACKGROUND AND OVERVIEW Social drivers of health (SDOH) are individual factors that directly or indirectly influence a person’s health outcomes. Research shows that SDOH factors, including access to quality nutrition, stable housing, basic utilities, transportation, and an environment free from …
BMT and Rehab CAR-T and Rehab Comprehensive Care of the Bone Marrow Transplant Patient Macy Hogan, PT, DPT Franciscan Health Objectives • To address special considerations for BMT patients to improve awareness, clinical reasoning, and standard of care when treating a BMT patient, particularly patients undergoing CAR-T therapy • To improve awareness of changes in …
PowerPoint Presentation Perspectives from CAR T Treaters and Referrers in an Evolving B-Cell Lymphoma Landscape Girish Kunapareddy, MD Hematologist/Oncologist Union Health Rita Assi, MD Assistant Professor of Medicine Indiana University Melvin and Bren Simon Comprehensive Cancer Center Daniel Wojenski, PharmD Medical Science Liaison, Cell Therapy Bristol Myers …